Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 311

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 311
---
 received in a Fundamental Transaction (as defined in the February 2025 Pre-Funded Warrant), then the holder will be given the same choice as to the consideration it receives upon any exercise of either the February 2025 Pre-Funded Warrants following such Fundamental Transaction. Right as a Stockholder.Except as otherwise provided in the February 2025 Pre-Funded Warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holders of the February 2025 Pre-Funded Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they exercise their February 2025 Pre-Funded Warrants. February 2025 Common Warrants The following summary of certain terms and provisions of the February 2025 Common Warrants that are is not complete and is subject to, and qualified in its entirety by, the provisions of the February 2025 Common Warrant, the form of which is filed as Exhibit 4.7 to the registration statement filed with the SEC on February 5, 2025. Prospective investors should carefully review the terms and provisions of the form of February 2025 Common Warrant for a complete description of the terms and conditions of the February 2025 Common Warrants. We issued and sold 127,551 February 2025 Common Warrants to purchase an aggregate of 127,551 shares of our Common Stock. Each February 2025 Common Warrant has an exercise price per share of $39.20 and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the February 2025 Common Warrants (the “Warrant Stockholder Approval”) which we obtained on May 29, 2025. The February 2025 Common Warrants will expire on the 5-year anniversary of the Warrant Stockholder Approval. The February 2025 Common Warrants will be exercisable in whole or in part by delivering to the Company a completed instruction form for exercise and complying with the requirements for exercise set forth in the February 2025 Common Warrant. Payment of the exercise price may be made in cash, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in the February 2025 Common Warrants. No Fractional Shares.No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the February 2025 Common Warrants. As to any fraction of